Clinical outcomes among initial survivors of cryptogenic new‐onset refractory status epilepsy (NORSE)
Costello D, Matthews E, Aurangzeb S, Doran E, Stack J, Wesselingh R, Dugan P, Choi H, Depondt C, Devinsky O, Doherty C, Kwan P, Monif M, O'Brien T, Sen A, Gaspard N. Clinical outcomes among initial survivors of cryptogenic new‐onset refractory status epilepsy (NORSE). Epilepsia 2024, 65: 1581-1588. PMID: 38498313, DOI: 10.1111/epi.17950.Peer-Reviewed Original ResearchActive epilepsyClinical outcomesMental health outcomesMonths post-dischargeMonths of dischargeTreatment strategiesAcute phaseHealth outcomesLonger-term outcomesGlobal disabilityPost-dischargeMinority of patientsTertiary care centerTailored treatment strategiesNature of treatmentSevere clinical syndromeCare centerDeterminants of outcomePsychiatric comorbiditiesWell-characterized casesFunctional outcomesSurvivorsInvestigated patientsFollow-upSpecialist centers